Evaluation of Efficacy and Determining Various Factors Associated with the Effective Use of Vitamin-K Antagonist Therapy in the Indian Population

Darisi S, A. T, George J, Ramaiah B
{"title":"Evaluation of Efficacy and Determining Various Factors Associated with the Effective Use of Vitamin-K Antagonist Therapy in the Indian Population","authors":"Darisi S, A. T, George J, Ramaiah B","doi":"10.26420/austinjclincardiolog.2021.1080","DOIUrl":null,"url":null,"abstract":"Aim: To assess the efficacy of Vitamin K antagonist to maintain stable INR in a tertiary care hospital. Methodology: All the patients who are on Vitamin K antagonists therapy for more than 6 months before the initiation of the study were included. Data, which include demographics, Personal history, medical history, medication history, Dietary habits, laboratory data (INR), and other relevant data, are collected. The laboratory results are further evaluated using the Rosendaal method and Time in Therapeutic Range, which was obtained which is evaluated, for assessing the use of medication, and other correlations were further made. Results and Discussion: The study showed a mean TTR of 25.638%, the mean TTR above and below the therapeutic range is 19.23% (±17.14), 55.11% (±29.64) respectively, this represents that the patients in the sample population are at higher risk of developing a new clot during the therapy with VKA, various chronic conditions such as Diabetes mellitus, the use of NSAIDs, PPI also showed a statistically significant difference on the patients TTR. Conclusion: Despite patients being therapeutically anticoagulated, based on the available data, many patients in the study population are at high risk of developing complications of anticoagulants and also the development of new clots even during the treatment, there are not many reports of TTR measurement in INDIAN population, The use of Vitamin K Antagonist comes with many limitations, many Newer Oral Anticoagulants (NOAC) can be used in patients as they are proven to be providing better control of TTR.","PeriodicalId":90445,"journal":{"name":"Austin journal of clinical cardiology","volume":"54 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin journal of clinical cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/austinjclincardiolog.2021.1080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To assess the efficacy of Vitamin K antagonist to maintain stable INR in a tertiary care hospital. Methodology: All the patients who are on Vitamin K antagonists therapy for more than 6 months before the initiation of the study were included. Data, which include demographics, Personal history, medical history, medication history, Dietary habits, laboratory data (INR), and other relevant data, are collected. The laboratory results are further evaluated using the Rosendaal method and Time in Therapeutic Range, which was obtained which is evaluated, for assessing the use of medication, and other correlations were further made. Results and Discussion: The study showed a mean TTR of 25.638%, the mean TTR above and below the therapeutic range is 19.23% (±17.14), 55.11% (±29.64) respectively, this represents that the patients in the sample population are at higher risk of developing a new clot during the therapy with VKA, various chronic conditions such as Diabetes mellitus, the use of NSAIDs, PPI also showed a statistically significant difference on the patients TTR. Conclusion: Despite patients being therapeutically anticoagulated, based on the available data, many patients in the study population are at high risk of developing complications of anticoagulants and also the development of new clots even during the treatment, there are not many reports of TTR measurement in INDIAN population, The use of Vitamin K Antagonist comes with many limitations, many Newer Oral Anticoagulants (NOAC) can be used in patients as they are proven to be providing better control of TTR.
在印度人群中有效使用维生素k拮抗剂治疗的疗效评价和确定各种相关因素
目的:评价维生素K拮抗剂维持三级医院稳定INR的疗效。方法:所有在研究开始前接受维生素K拮抗剂治疗超过6个月的患者都被纳入研究。收集的数据包括人口统计、个人病史、病史、用药史、饮食习惯、实验室数据(INR)和其他相关数据。使用Rosendaal方法和治疗范围内时间对实验室结果进行进一步评估,以评估药物的使用,并进一步建立其他相关性。结果与讨论:研究显示TTR平均值为25.638%,治疗范围内TTR平均值为19.23%(±17.14),治疗范围内TTR平均值为55.11%(±29.64),这表明样本人群中患者在VKA治疗期间发生新血栓的风险较高,各种慢性疾病如糖尿病、使用非甾体抗炎药、PPI对患者TTR也有统计学差异。结论:尽管患者治疗实际上,基于可用的数据,许多患者在研究高危人口发展中抗凝并发症甚至还开发新凝块在治疗期间,没有很多的报告测量竞技场队伍在印度人口,维生素K拮抗剂的使用有很多局限性,许多新的口服抗凝血剂(NOAC)可以使用在病人被证明是竞技场队伍提供更好的控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信